Objective
to examine effect of Ticagrelor alone vs Ticagrelor + Aspirin regarding clinically relevant bleeding
Study
prospective, multicentre, placebo-controlled, randomised trial
Population
patients who were at high risk for bleeding or ischemic event and undergone PCI
Endpoints
Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding
Conclusion
ticagrelor monotherapy was associated with a lower incidence of clinically relevant bleeding than ticagrelor plus aspirin
Mehran et al. N Engl J Med. 2019;381:2032-42
